Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable…
In Conversation
Owned completely by the LEO Foundation, LEO Pharma is an extremely patient-centric company focused primarily in the dermatology area. Kristian Hart-Hansen, general manager of LEO Pharma…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these…
Raúl Díaz-Varela is the CEO of Kern Pharma and has served as president of Spain’s generics association AESEG since 2008. He speaks to us about the…
Jesús Sobrino was appointed general manager of UCB Iberia in 2010, at the same time the pharma market began to seriously contract in Spain. Sobrino discusses…
PharmaBoardroom first interviewed Erik Lommerde as general manager of Novo Nordisk Netherlands four years ago. In his new role as general manager of Novo Nordisk Spain…
Invest in Catalonia discuss the Spanish region’s track record when it comes to the pharmaceutical and biotech sectors, where investment is going today in the region,…
Walther von Plettenberg, general manager of the German-Spanish Chamber of Commerce in Spain, traces the history of the organization’s activity and highlights the efforts of the…
Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully…
Emilio Lora-Tamayo, president of the Spanish National Research Council (CSIC), outlines Spain’s current strengths and weaknesses in the areas of research and innovation.
Despite a number of setbacks in public funding as a result of Spain’s recession, the Spanish National Biotechnology Center (CNB) has continued to remain at the…
